Generic BIOPHARMA: Generic Biopharmaceuticals, Biosimilars, Follow-on Biologics, Biogenerics, Follow-on Proteins, Biocomparables, Off-patent Biopharmaceuticals

BIOSIMILARS.com
Biosimilars, Follow-on Biologics, Follow-on Proteins, Subsequent Entry Biologics, Similar Biological Medicinal Products, BioBetters, Biogenerics, Generic Biopharmaceuticals, etc.

The Biosimilars Information Resource for the Biopharmaceutical Industry [embryonic site under construction]

Bosimilars/Biobetters Pipeline Database

Coming this spring: The most comprehensive biosimilars and biobetters pipeline reference (database). Authored by this site's Webmaster and the author of BIOPHARMA, the only biopharmaceuticals information resource/reference (at www.biopharma.com).

Some preliminary top level data are presented below. For further information, please contact the Webmaster, Ron Rader.

Biosimilars/Biobetters Pipeline Database - Preliminary Top Level Data (2/2013)

Database Product Entries by Class (n = 998)

biosimilars = 484
biobetters = 367
ref. products = 117
total pipeline products (biosimilars + biobetters) = 874

Note, this study only covers recombinant proteins and a few other protein products. Vaccines, blood-derived, cultured cells and tissues and other types of biologics are not included!

Note, products can have multiple companies involved.

Companies With the Largest Pipelines

Biosimilars (10 or more)
Harvest Moon Pharmaceuticals USA, Inc.	28
BioXpress Therapeutics S.A.	19
Inbiopro Solutions Pvt Ltd.	14
Biocon Ltd.	14
Bio Sidus S.A.	12
Green Cross Corp.	11
Dong-A Pharmaceutical.	11
Bioton S.A..	11
AXXO GmbH	11
LG Life Sciences Ltd.	10
Chemo Group (Grupo Insud )	10
Amega Biotech	10

Biobetters (8 or more)
Novo Nordisk A/S	16
Roche/Genentech	14
Biogen Idec	13
Bolder BioTechnology, Inc.	12
Amega Biotech	11
Lilly, Eli & Co.	10
Pfizer Inc.	9
PROLOR Biotech, Inc.	9
Merck KGaA	9
Baxter	8

Contact information:

Ronald A. Rader
President
Biotechnology Information Institute
1700 Rockville Pike, Suite 400
Rockville, MD 20852
Phone: 301-424-0255
E-mail: biotech@biosimilars.com
other Web sites: www.BIOPHARMA.com; www.BIOPHARMACOPEIA.com; www.bioinfo.com

Biosimilars.com

Biosimilars Pipeline - products in development; see the left column
Biosimilar terminology and definitions - background
Glossary of Biosimilar-Related Terms - simple definitions
BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets: - the only information resource specializing in biopharmaceuticals; the reference products' reference
Licensing Opportunities - products, technologies and patents
U.S. BIOPHARMACOPEIA Registry of Biopharmaceutical Products: agent and product nomenclature information (proposed)
Product Documentation Library - [coming] descriptive product information from the only fully authoritative sources: manufacturers and, secondarily, regulatory agencies
News Blog: - miscellaneous news and commentary
Information Resources - links

Related articles by the Webmaster:

"Nomenclature of Biosimilars Will Be Highly Controversial" , BioProcess International, June 2011
"What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic? Part 1: Introduction and Basic Paradigms Introduction and Basic Paradigms" , BioProcess International, March 2007
""What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic? Part 2: Information, Nomenclature, Perceptions, and the Markets" , BioProcess International, March 2007
"Re(Defining) Biopharmaceutical ," Nature Biotechnology, July 2008
"What is a Biopharmaceutical? Part 1: (Bio)Technology-Based Definitions," BioExecutive, March 2005
"What is a Biopharmaceutical? Part 2: Company and Industry Definitions," BioExecutive, May 2005
"Nomenclature and Registry Systems for Biopharmaceuticals, Biosimilars and Biogenerics"
"Biopharmaceuticals: Lack of Information Disclosure Confounds Public Trust, Particularly in the Context of Biosimilars:" guest editorial, BioWorld Perspectives, May 1, 2008

Need a Consultant With Biosimilars Expertise? - The Web master, Ronald A. Rader, is available. See his short bio and full resume. Mr. Rader is the author of BIOPHARMA, the only information resource/reference specializing in biopharmaceuticals (see www.biopharma.com), has authored the defining articles concerning biopharmaceuticals and biosimilars/FOBs (e.g., see the "What is...", "(Re)Defining" and related abstracts/links above), and is a world-class expert concerning biopharmaceutical information, products, techologies, and related market, technology and policy assessments.

Sponsors needed! Without financing and/or collaboration with a view towards the long term, we (Biotech. Info. Inst.) do not foresee commercial viability for our solely developing biosimilar information resources. There simply are too few involved with too few opportunities for cost-recovery, much less profit; and there are no plans to devalue this site by taking advertising. Thus, corporate or other funding or collaboration is needed. We envision developing the best (or only) Web site/database/reference providing substantive authoritive, including (bio)technical, information about biosimilars (and biobetters and biogenerics). To learn more, contact Ron Rader.

Contact information: